Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DCLL9718A
- Development stage
- Discontinued
- Lead developer
- Genentech
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
DCLL9718A is an antibody-drug conjugate (ADC) developed for the treatment of acute myeloid leukemia (AML). It comprises a humanized IgG1 anti–C-type lectin-like molecule-1 (CLL-1) monoclonal antibody (MCLL0517A, also known as hu6E7.N54A), which targets CLL-1, a receptor expressed on monocytes, neutrophils, and AML blast cells but not on hematopoietic stem cells. The antibody is linked via a cleavable disulfide-labile linker to a pyrrolobenzodiazepine (PBD) dimer payload, a DNA alkylating agent. This design allows for selective cytotoxicity against AML blasts, with preclinical and early phase clinical development evidence demonstrating target engagement, measurable pharmacodynamics (notable reduction in monocytes and neutrophils), and stable drug conjugation in vivo and in vitro[1][2][3][10].
- Other names
- anti-CLL1-PBD ADC DCLL9718Santi-CLL-1-PBD ADC DCLL9718Santi-CLL 1-PBD ADC DCLL9718S
02
Targets
CLEC12A
Beyond the preview
Go deeper on DCLL9718A.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DCLL9718A.